NCT04848506

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

ENROLLING_BY_INVITATIONPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2021-05-06Est. Completion: 2029-03

Enrollment target: 900 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
UC San Diego Health - Sulpizio Cardiovascular Center, La Jolla, California, United States
Cedar-Sinai Medical Center, Los Angeles, California, United States
Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States
UCLA Health System - UCLA Cardiovascular Center, Los Angeles, California, United States
UCSF Medical Center, San Francisco, California, United States
Yale New Haven Hospital, New Haven, Connecticut, United States
MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
Holy Cross Hospital / Cardiology Associates, Fort Lauderdale, Florida, United States
Emory Clinic, Atlanta, Georgia, United States
Piedmont Fayette Hospital, Fayetteville, Georgia, United States
The Queen's Medical Center, Honolulu, Hawaii, United States
Northwestern University, Chicago, Illinois, United States

Hypertrophic CardiomyopathyLeft Ventricular Outflow ObstructionSystolic Anterior Motion

This is an early study of a catheter-based minimally invasive procedure called SESAME to slice thick heart muscle as des…

Washington D.C., United StatesEst. completion Mar 1, 2029

Non-obstructive Hypertrophic Cardiomyopathy

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess…

La Jolla, United StatesEst. completion Dec 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.